Strides Pharma Inc's Chestnut Ridge facility gets 4 observations from USFDA
These observations are procedural in nature and the company does not anticipate any impact on supply of its commercial products
These observations are procedural in nature and the company does not anticipate any impact on supply of its commercial products
The audit was completed with zero critical and zero major observations
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
The said inspection concluded with Zero Form 483 observation
The FDA’s review also revealed delays in Philips’ internal investigations, with 54 inquiries failing to meet targeted completion dates—23 of which were delayed by more than 100 days
The Cranbury facility represents a strategic advancement of the company's operations in the Unted States
New offering to debut at the 32nd ESGCT Congress, October 7–10, 2025, in Seville, Spain
States exhorted to ensure rational use of cough syrups, particularly among children, as most coughs are self-limiting and do not require pharmacological treatment
With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations
The association called for an end to the constant issuance of regulatory circulars that make operations unpredictable and capital-intensive.
Subscribe To Our Newsletter & Stay Updated